Cardiac troponin testing in the management of patients infected with Sars-Cov-2
1 Laboratory of Biochemistry of Joseph Ravoahangy Andrianavalona University Hospital Antananarivo, Madagascar.
2 Laboratory of Joseph Ravoahangy Andrianavalona University Hospital Antananarivo, Madagascar.
3 Laboratory of Training and Research in Medical Biology, University of Antananarivo, Madagascar.
Research Article
GSC Biological and Pharmaceutical Sciences, 2022, 19(01), 056–060.
Article DOI: 10.30574/gscbps.2022.19.1.0071
Publication history:
Received on 09 February 2022; revised on 04 April 2022; accepted on 06 April 2022
Abstract:
Coronavirus disease 2019 (COVID-19) is a viral zoonosis caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). High sensitive Troponin cardiac (hs-cTn) is a biomarker frequently measured during the management of COVID-19. We conducted a descriptive retrospective study at the Paraclinical Service of Training and Researches in Biochemistry at the University Hospital Center of Joseph Ravoahangy Andrianavalona Madagascar over a period of five months. Our objective was to describe the modalities and the relevance of the prescription of hs-cTn determination within the intensive care units of the hospital. Of the 42 patient files collected in our work, we found a slight male predominance (sex ratio = 1.47) and the average age was 56.8 years. In 18 patients, hs-cTn was positive and among the 19 patients who died as a result of their disease 11 had elevated plasma troponin levels. During COVID 19, troponin assay should be prescribed appropriately to enhance the management of patients in a developing country like Madagascar where the cost of assaying this biomarker remains high
Keywords:
Biochemistry; COVID-19; Highly sensitive Troponin; Antananarivo
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
